 Zosano Pharma Corporation NASDAQ: ZSAN announced the publication of Phase 1 trial data of influenza vaccine in the Journal of Vaccines and Immunology. The data demonstrated that a low dose of a trivalent influenza vaccine administered via its transdermal microneedle system produced antibody levels and was generally well tolerated. 